Liso-Cel PDUFA 3-Month Delay; BMS Q1 2020 Call Summary
Here is a brief preview of this blast: On Thursday, May 6, BMS held their Q1 2020 earnings call, providing an update on their CAR-T program. As announced on May 5, the company explained that the liso-cel PDUFA date has been pushed back three months to November 16, 2020 to allow the FDA time to review additional clinical data. Meanwhile, BMS provided brief commentary on their BCMA CAR-Ts ide-cel and orva-cel. Below, FENIX provides highlights and analysis from the call, particularly in the context of the liso-cel PDUFA setback in a field being led by Yescarta and Kymriah.